

2026 Joint Pre-ACTRIMS-ECTRIMS Course

20 October 2026
Toronto, Canada

PRELIMINARY PROGRAMME

An educational programme by



European
Charcot
Foundation



Med-Ex Learning
Education & Events



Aim of the Course

The Pre-ACTRIMS-ECTRIMS course is an annual event aimed at providing an update on the main novelties of the year in the field of MS. The 2026 edition will particularly focus on new evidence on immunopathogenetic mechanisms, imaging, fluid biomarkers and new therapeutic approaches in relation to the MS continuum. The 'controversies' session will cover the main 'hot topics' that are currently debated, including MS prodromes, progression independent from relapses (PIRA) as a new clinical outcome, the impact of artificial intelligence and machine learning on the improvement of MS detection and prediction, and new epidemiological data and treatment algorithm about late onset MS (LOMS). Since 2020, Med-Ex Learning has been providing this course in collaboration with the European Charcot Foundation, and we plan to continue this tradition in 2026 and in the future.



Target Audience

This Workshop is designed for neurologists and other healthcare professionals with specific interest in Multiple Sclerosis.



Learning Objectives

- Describing the role of central chronic inflammation in the progressive phase of MS and the mechanism of action of new drugs
- Addressing new diagnostic and treatment challenges in special populations and conditions (radiological isolated syndrome, pregnancy, elderly...)
- Understanding how to classify disease courses and estimate prognosis in relation to new fluid and digital biomarkers of disease progression

Scientific Organisers

Hans Peter Hartung

Professor of Neurology
Department of Neurology
Heinrich-Heine University
and
Department of Conservative Medicine
Dusseldorf University Hospital
Co-President of the European Charcot
Foundation
Dusseldorf, Germany

Xavier Montalban

Professor of Neurology
Neurology Department
Multiple Sclerosis Centre of Catalonia
(Cemcat)
and
Vall d'Hebron Barcelona Hospital Campus
Co-President of the European Charcot
Foundation
Barcelona, Spain

Accreditation



The programme will be submitted for CME accreditation to the European Accreditation Council for Continuing Medical Education (EACCME®) and the American Accreditation Council for Continuing Medical Education (ACCME).

Scientific Secretariat

Med-Ex Learning

Rome, Italy
info@medexlearning.com

Registration

Registration for in-person attendance is free of charge but limited places are available.

Pre-register now to be among the first to receive programme updates, early access to registration, and key information as the 2026 edition takes shape.



Preliminary Programme

- 13.30 Welcome & Opening
H.P. Hartung, Germany and X. Montalban, Spain
- Session 1: Relapsing remitting and progressive MS - One or Two Diseases?**
Chair: H.P. Hartung, Germany
- 13.45 L1 - New evidence on mechanistic aspects of neuroinflammation and neurodegeneration
Speaker to be announced
- 14.05 L2 - Imaging biomarkers
D. Ontaneda, USA
- 14.25 L3 - Body fluid biomarkers conceptual and practical
J. Kuhle, Switzerland
- 14.45 L4 - New Diagnostic criteria and revision of the classification of courses
X. Montalban, Spain
- 15.05 L5 - Optimization of treatments in real life settings
J. Oh, Canada
- 15.25 L6 - From neuroimmunology to future treatment targets
A. Bar Or
- 15.45 Q&A
- 15.55 *Coffee break*



Session 2: Controversies in MS

Chair: X. Montalban, Spain

- 16.10 L7 - MS prodromes: sensitivity or specificity?
Speaker to be announced
- 16.30 L8 - PIRA: inflammation or neurodegeneration?
C. Tur, Spain
- 16.50 L9 - Predicting disability: what's the role of artificial intelligence?
C. Granziera, Switzerland
- 17.10 L10 - Late onset MS: a new clinical entity?
M. Tintorè, Spain
- 17.30 L11 - Treatment de-escalation: who, when, why?
H.P. Hartung, Germany
- 17.50 L12 - Pregnancy management in MS: what's new?
M. Houtchens, US
- 18.00 Q&A
- 18.15 Wrap up
- 18.20 *End of the day*



Med-Ex Learning
Education & Events

Copyright © Med-Ex Learning, 2026. All rights reserved.